S&P 500   4,574.38 (+-0.01%)
DOW   35,633.69 (-0.34%)
QQQ   382.64 (+0.93%)
AAPL   149.60 (+0.19%)
MSFT   325.75 (+5.04%)
FB   315.08 (-0.23%)
GOOGL   2,949.53 (+5.86%)
TSLA   1,037.92 (+1.91%)
AMZN   3,423.19 (+1.40%)
NVDA   247.33 (+0.06%)
BABA   170.21 (+0.13%)
NIO   39.73 (-1.83%)
CGC   12.95 (-1.67%)
GE   104.20 (-3.02%)
AMD   123.75 (+0.67%)
MU   68.55 (-0.57%)
T   25.15 (-0.87%)
F   15.66 (-1.76%)
ACB   6.84 (-2.70%)
DIS   170.68 (-0.79%)
PFE   42.85 (-1.63%)
BA   208.70 (-0.53%)
AMC   34.84 (-3.36%)
S&P 500   4,574.38 (+-0.01%)
DOW   35,633.69 (-0.34%)
QQQ   382.64 (+0.93%)
AAPL   149.60 (+0.19%)
MSFT   325.75 (+5.04%)
FB   315.08 (-0.23%)
GOOGL   2,949.53 (+5.86%)
TSLA   1,037.92 (+1.91%)
AMZN   3,423.19 (+1.40%)
NVDA   247.33 (+0.06%)
BABA   170.21 (+0.13%)
NIO   39.73 (-1.83%)
CGC   12.95 (-1.67%)
GE   104.20 (-3.02%)
AMD   123.75 (+0.67%)
MU   68.55 (-0.57%)
T   25.15 (-0.87%)
F   15.66 (-1.76%)
ACB   6.84 (-2.70%)
DIS   170.68 (-0.79%)
PFE   42.85 (-1.63%)
BA   208.70 (-0.53%)
AMC   34.84 (-3.36%)
S&P 500   4,574.38 (+-0.01%)
DOW   35,633.69 (-0.34%)
QQQ   382.64 (+0.93%)
AAPL   149.60 (+0.19%)
MSFT   325.75 (+5.04%)
FB   315.08 (-0.23%)
GOOGL   2,949.53 (+5.86%)
TSLA   1,037.92 (+1.91%)
AMZN   3,423.19 (+1.40%)
NVDA   247.33 (+0.06%)
BABA   170.21 (+0.13%)
NIO   39.73 (-1.83%)
CGC   12.95 (-1.67%)
GE   104.20 (-3.02%)
AMD   123.75 (+0.67%)
MU   68.55 (-0.57%)
T   25.15 (-0.87%)
F   15.66 (-1.76%)
ACB   6.84 (-2.70%)
DIS   170.68 (-0.79%)
PFE   42.85 (-1.63%)
BA   208.70 (-0.53%)
AMC   34.84 (-3.36%)
S&P 500   4,574.38 (+-0.01%)
DOW   35,633.69 (-0.34%)
QQQ   382.64 (+0.93%)
AAPL   149.60 (+0.19%)
MSFT   325.75 (+5.04%)
FB   315.08 (-0.23%)
GOOGL   2,949.53 (+5.86%)
TSLA   1,037.92 (+1.91%)
AMZN   3,423.19 (+1.40%)
NVDA   247.33 (+0.06%)
BABA   170.21 (+0.13%)
NIO   39.73 (-1.83%)
CGC   12.95 (-1.67%)
GE   104.20 (-3.02%)
AMD   123.75 (+0.67%)
MU   68.55 (-0.57%)
T   25.15 (-0.87%)
F   15.66 (-1.76%)
ACB   6.84 (-2.70%)
DIS   170.68 (-0.79%)
PFE   42.85 (-1.63%)
BA   208.70 (-0.53%)
AMC   34.84 (-3.36%)
NYSE:USNA

USANA Health Sciences Stock Forecast, Price & News

$93.71
-6.02 (-6.04 %)
(As of 10/27/2021 02:33 PM ET)
Add
Compare
Today's Range
$92.82
$97.60
50-Day Range
$87.40
$99.49
52-Week Range
$73.00
$107.85
Volume
1,379 shs
Average Volume
87,707 shs
Market Capitalization
$1.88 billion
P/E Ratio
14.13
Dividend Yield
N/A
Beta
0.85
30 days | 90 days | 365 days | Advanced Chart
Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.


USANA Health Sciences logo

About USANA Health Sciences

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group. The Optimizers Nutritionals category consists of targeted supplements that support cardiovascular health, skeletal and structural health, and digestive health. The Foods Nutritionals category includes low-glycemic meal replacement shakes, snack bars, and other related products that provide optimal macro-nutrition. The Personal Care and Skincare includes science-based personal care products and Celavive. The All Others includes materials and online tools that are designed to assist Associates in building their businesses and in marketing products. The firm's brand include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
Personal Products
Sector
Medical
CUSIP
90328M10
Employees
1,943
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$6.70 per share
Book Value
$20.99 per share

Profitability

Net Income
$124.66 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.88 billion
Next Earnings Date
2/8/2022 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

539th out of 1,365 stocks

Medicinals & Botanicals Industry

1st out of 19 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

Is USANA Health Sciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than USANA Health Sciences?

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for USANA Health Sciences
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings data on Tuesday, October, 26th. The company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.06. USANA Health Sciences had a trailing twelve-month return on equity of 33.65% and a net margin of 11.09%. During the same period in the prior year, the firm earned $1.44 earnings per share.
View USANA Health Sciences' earnings history
.

How has USANA Health Sciences' stock price been impacted by Coronavirus?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, USNA stock has increased by 34.2% and is now trading at $93.77.
View which stocks have been most impacted by COVID-19
.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences announced that its board has initiated a share repurchase program on Tuesday, February 9th 2021, which allows the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 8.2% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's management believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2021 earnings guidance on Tuesday, October, 26th. The company provided earnings per share (EPS) guidance of $5.800-$6.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.930. The company issued revenue guidance of $1.18 billion-$1.20 billion, compared to the consensus revenue estimate of $1.19 billion.

What price target have analysts set for USNA?

2 brokers have issued twelve-month price targets for USANA Health Sciences' shares. Their forecasts range from $122.00 to $126.00. On average, they anticipate USANA Health Sciences' stock price to reach $124.00 in the next year. This suggests a possible upside of 32.2% from the stock's current price.
View analysts' price targets for USANA Health Sciences
or view top-rated stocks among Wall Street analysts.

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Kevin G. Guest, Chairman & Chief Executive Officer
  • Jim Brown, President
  • Walter Noot, Chief Operating Officer
  • G. Douglas Hekking, Chief Financial Officer
  • Robert Andrew Sinnott, Chief Scientific Officer

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.16%), Robeco Institutional Asset Management B.V. (0.12%), Denali Advisors LLC (0.11%), Exchange Traded Concepts LLC (0.09%), Strs Ohio (0.05%) and State of Alaska Department of Revenue (0.04%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences
.

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Denali Advisors LLC, and Virginia Retirement Systems ET AL. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences
or view top insider-selling stocks.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Koshinski Asset Management Inc., State of Alaska Department of Revenue, Exchange Traded Concepts LLC, Strs Ohio, and Louisiana State Employees Retirement System.
View insider buying and selling activity for USANA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $93.77.

How much money does USANA Health Sciences make?

USANA Health Sciences has a market capitalization of $1.88 billion and generates $1.13 billion in revenue each year. The company earns $124.66 million in net income (profit) each year or $5.86 on an earnings per share basis.

How many employees does USANA Health Sciences have?

USANA Health Sciences employs 1,943 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

Where are USANA Health Sciences' headquarters?

USANA Health Sciences is headquartered at 3838 West Parkway Blvd, Salt Lake City UT, 84120.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at (801) 954-7100 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.